Skip to content

Study on antithrombotic status and prognosis in patients with atrial fibrillation and coronary heart disease

Study on antithrombotic status and prognosis in patients with atrial fibrillation and coronary heart disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015087
Enrollment
Unknown
Registered
2018-03-07
Start date
2018-05-01
Completion date
Unknown
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation and coronary heart disease

Interventions

Antiplatelet therapy group:Antiplatelet therapy
Anticoagulant and antiplatelet therapy group:Anticoagulant and antiplatelet therapy

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with acute coronary syndrome who are hospitalized, including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina or coronary intervention; 2. High risk of non-valvular atrial fibrillation, electrocardiogram or 24-hour ambulatory electrocardiogram in the last 3 months diagnosed as atrial fibrillation. And CA2DS2-Vsc score of men = 1, women = 2; 3.Sign the written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Estimated life expectancy is less than 2 years; 2. There is a condition that can cause severe bleeding; 3. Poor drug compliance.

Design outcomes

Primary

MeasureTime frame
major bleeding;minor bleeding;

Secondary

MeasureTime frame
Non-fatal thromboembolic events;all cause death;

Countries

China

Contacts

Public ContactYihong Sun

China-Japan Friendship Hospital

yihongsun72@163.com+86 13811224720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026